Qu Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Qu Biologics's estimated annual revenue is currently $2.2M per year.
- Qu Biologics's estimated revenue per employee is $77,500
- Qu Biologics's total funding is $30M.
Employee Data
- Qu Biologics has 28 Employees.
- Qu Biologics grew their employee count by 17% last year.
Qu Biologics's People
Name | Title | Email/Phone |
---|
Qu Biologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Qu Biologics?
Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). SSIs aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. The company has initiated three clinical trials in Crohn's disease, ulcerative colitis and lung cancer. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally. We are always interested in talented biotechnology professionals and know that some of the best team members can be found when you're not looking for them. For Qu, finding the right team member is not about matching a resume to a checklist of skills, it's about integrity and character. If you have big ideas, love a fast-paced innovative environment and you're up for the challenge, we want to hear from you. Send us your resume and a detailed cover letter telling us about yourself and how you feel you could contribute. Applications can be sent, in confidence, to jobs@qubiologics.com.
keywords:N/A$30M
Total Funding
28
Number of Employees
$2.2M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Qu Biologics News
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and...
VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is rece ...
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversub ...
VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.5M | 31 | 3% | N/A |
#2 | N/A | 33 | 43% | N/A |
#3 | $2.8M | 35 | -12% | N/A |
#4 | $9.9M | 35 | 0% | N/A |
#5 | $8.1M | 35 | 0% | N/A |